Table 1 Summary of previous reports on IMT of the stomach in adults
No. | Author | Year | Age | Sex | Maximum tumor size (cm) | Preoperative diagnosis | Treatment | ALK immunostaining | IgG4/IgG ratio | Observation period | Recurrence |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Kim et al. [4] | 2004 | 26 | M | 8.0 | N.D | TG, DP, SP, TC | N.D | N.D | 5 weeks | Peritoneal dissemination recurrence |
2 | Leon et al. [5] | 2006 | 50 | F | 7.0 | N.D | DG | N.D | N.D | 2 years | None |
3 | Park et al. [6] | 2008 | 55 | F | 8.5 | N.D | PR | Negative | N.D | N.D | N.D |
4 | Shah et al. [7] | 2008 | 80 | F | 1.5 | N.D | EMR | N.D | N.D | N.D | N.D |
5 | Shi et al. [8] | 2010 | 40 | F | 5.8 | N.D | PR | Positive | N.D | 4 years | None |
6 | Shi et al. [8] | 2010 | 45 | M | 5.5 | N.D | PR | Positive | N.D | 2.6 years | None |
7 | Shi et al. [8] | 2010 | 40 | M | 6.3 | N.D | PR | Positive | N.D | 3.3 years | None |
8 | Shi et al. [8] | 2010 | 42 | M | 8.0 | N.D | PR | Positive | N.D | 2 years | Local recurrence at 12 months |
9 | Shi et al. [8] | 2010 | 36 | M | 4.5 | N.D | PR | Positive | N.D | 5 years | None |
10 | Albayrak et al. [9] | 2010 | 56 | F | 6.0 | N.D | PR | Negative | N.D | 8 months | None |
11 | Fong et al. [10] | 2010 | 56 | M | 3.0 | N.D | PR | N.D | N.D | N.D | N.D |
12 | Lee et al. [11] | 2011 | 42 | F | 5.5 | GIST susp. | Endoscopic local tumor excision | N.D | N.D | N.D | N.D |
13 | Riberio et al. [12] | 2012 | 37 | F | 7.3 | GIST susp. | DG | Positive | N.D | N.D | None |
14 | Jain et al. [13] | 2012 | 35 | F | 1.1 | N.D | PR | Negative | N.D | 7 months | None |
15 | Bijelovic et al. [14] | 2013 | 43 | F | 2.5 | N.D | DG | Positive | N.D | 24 months | None |
16 | Arslan et al. [15] | 2013 | 65 | F | 11.4 | N.D | PR | Positive | N.D | 37 months | None |
17 | Chong et al. [16] | 2013 | 59 | M | 10.0 | N.D | PR | Negative | N.D | N.D | N.D |
18 | Katakwar et al. [17] | 2014 | 45 | M | 5.7 | GIST susp. | DG | Positive | N.D | N.D | N.D |
19 | Chen et al. [18] | 2014 | 50 | F | 22.0 | N.D | TG, SP | Negative | N.D | 4 months | N.D |
20 | Kim et al. [19] | 2015 | 25 | M | 4.0 | N.D | LPG | Negative | < 0.4 | 18 months | None |
21 | Mohammad et al. [20] | 2016 | 18 | M | 10.0 | Submucosal tumor susp. | LPG, SP | Negative | N.D | 9 months | None |
22 | Jadhav et al. [21] | 2017 | 18 | M | 8.6 | Gastric leiomyoma, GIST susp. | PR | Negative | N.D | 5 years | None |
23 | Ning et al. [22] | 2017 | 50 | F | 3.0 | Ectopic pancreas | ESD | N.D | N.D | 2 years | None |
24 | Fan et al. [23] | 2017 | 37 | M | 4.5 | GIST susp. | TG | Positive | < 0.4 | 6 months | None |
25 | Lee et al. [24] | 2018 | 35 | F | 2.5 | N.D | PR | N.D | N.D | 3 years | None |
26 | Lee et al. [24] | 2018 | 39 | F | 2.0 | N.D | PR | N.D | N.D | 3 years | None |
27 | Lee et al. [24] | 2018 | 38 | F | 4.2 | N.D | PR | N.D | N.D | 4 years | None |
28 | Lee et al. [24] | 2018 | 36 | F | 3.0 | N.D | PR | N.D | N.D | 6 years | None |
29 | Lee et al. [24] | 2018 | 43 | F | 3.4 | N.D | PR | N.D | N.D | 11 years | None |
30 | Hayashi et al. [25] | 2018 | 53 | F | 2.0 | Scirrhous gastric cancer susp. | PR(combined laparoscopic and endoscopic method) | Positive | N.D | N.D | N.D |
31 | Song et al. [26] | 2020 | 43 | M | 4.5 | N.D | DG | N.D | N.D | 70 months | None |
32 | Hanjog et al. [27] | 2021 | 25 | F | 10.0 | GIST susp. | DG | N.D | N.D | 6 months | None |
33 | Wang et al. [28] | 2021 | 22 | F | 3.2 | N.D | N.D | Positive | N.D | 34 months | None |
34 | Wang et al. [28] | 2021 | 41 | M | 6.1 | N.D | N.D | Positive | N.D | 12 months | None |
35 | Wang et al. [28] | 2021 | 27 | M | 3.2 | N.D | N.D | Positive | N.D | 38 months | None |
36 | Flores-Trujillo et al. [29] | 2022 | 52 | F | 7.6 | Adenocarcinoma susp. | DG | Negative | N.D | N.D | None |
37 | Our case | 2023 | 47 | M | 2.7 | GIST susp. | PR(combined laparoscopic and endoscopic method) | Positive | > 0.5 | 17 months | None |